Volume 2.48 | Dec 23

Mammary Cell News 2.48 December 23, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Penn Researchers Identify Potential Target for Breast Cancer Therapy  ShareThis
Researchers report that a protein called P-Rex1 is crucial for signal transmission from ErbB receptors. What’s more, they found that P-Rex1 is overexpressed in nearly 60 percent of breast cancer samples tested and patients whose tumors express P-Rex1 were more likely to develop metastasis, compared with those whose tumors did not express P-Rex1. [Press release from the University of Pennsylvania School of Medicine discussing online prepublication in Molecular Cell]



Facebook  Cell Therapy News is now on Facebook. Join us!

Twitter Follow us on Twitter! @MammaryCell

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at [email protected]


Gene Alteration Identified that Predisposes to Syndrome with High Risk of Cancer
Researchers have identified a new genetic alteration that predisposes individuals to Cowden syndrome, a rare disorder that is characterized by high risks of breast, thyroid and other cancers. [Press release from EurekAlert! discussing online prepublication in The Journal of the American Medical Association]

Key Information About Breast Cancer Risk and Development Is Found in “Junk” DNA
A new genetic biomarker that indicates an increased risk for developing breast cancer can be found in an individual’s “junk” (non-coding) DNA, according to a new study. [Press release from the Virginia Bioinformatics Institute at Virginia Tech discussing online prepublication in Breast Cancer Research and Treatment]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


TSPYL5 Suppresses p53 Levels and Function by Physical Interaction with USP7
Here, researchers report that high TSPYL5 (TSPY-like 5) expression is an independent marker of poor outcome in breast cancer. [Nat Cell Biol]

Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast Cancer
Here, researchers identify the PIP3-G(beta)(gamma)-dependent Rac-GEF P-Rex1 as an essential mediator of Rac1 activation, motility, cell growth, and tumorigenesis driven by ErbB receptors in breast cancer cells. [Mol Cell]

Linking Transgene Expression of Engineered Mesenchymal Stem Cells and Angiopoietin-1-Induced Differentiation to Target Cancer Angiogenesis
When injected into the peripheral circulation of mice with either, orthotopic pancreatic or spontaneous breast cancer, the engineered mesenchymal stem cells (MSCs) were actively recruited to growing tumor vasculature and induced the selective expression of either reporter red florescent protein or suicide genes [herpes simplex virus-thymidine kinase (TK) gene] when the adoptively transferred MSC developed endothelial-like characteristics. [Ann Surg]

Recovery of Anoikis in Src-Transformed Cells and Human Breast Carcinoma Cells by Restoration of the SIRP(Alpha)1/ SHP-2 Signaling System
In this study, researchers investigated the role of the protein tyrosine phosphatase SHP-2 in signal regulatory protein alpha1 activity. [Cancer Res]

A Mammaglobin-A Targeting Agent for Non-Invasive Detection of Breast Cancer Metastasis in Lymph Nodes
Here, researchers describe an imaging platform for non-invasive assessment of axillary lymph node status, eliminating the need for surgical examination of patients to rule out nodal involvement. [Cancer Res]

Na(v)1.5 Enhances Breast Cancer Cell Invasiveness by Increasing NHE1-Dependent H+ Efflux in Caveolae
Here, researchers showed that the Na+/H+ exchanger type 1 (NHE1) was an important regulator of H+ efflux in breast cancer cells MDA-MB-231 and that its activity was increased by Na(v)1.5. [Oncogene]

Hedgehog Signaling (Hh) Induced by Breast Cancer Cells Promotes Osteoclastogenesis and Osteolysis
In the present study researchers show that the Hh ligands secreted by breast cancer cells promote osteoclast differentiation and potentiate the activity of mature osteoclasts. [J Biol Chem]

A Long AAAG Repeat Allele in the 5′ UTR of the ERR-Gamma Gene Is Correlated with Breast Cancer Predisposition and Drives Promoter Activity in MCF-7 Breast Cancer Cells
The study indicates that the AAAG tetranucleotide repeat polymorphism in estrogen-related receptor-gamma gene 5′ UTR region may be a new biomarker for genetic susceptibility to breast cancer. [Breast Cancer Res Treat]


Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After Prior HER2-Directed Therapy
This report describes a single-arm phase II study (TDM4258g) that assessed efficacy and safety of intravenous T-DM1 (3.6 mg/kg every 3 weeks) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had tumor progression after prior treatment with HER2-directed therapy and who had received prior chemotherapy. [J Clin Oncol]

Quality of Life After Breast Cancer Diagnosis and Survival
The purpose of this study was to examine the association of quality of life after diagnosis of breast cancer with mortality and recurrence. [J Clin Oncol]


Quantum Immunologics Announces Appointment of Dr. George Peoples to Scientific Advisory Board
Quantum Immunologics, Inc. (QI), a Tampa, FL-based company currently engaged in an FDA-authorized clinical study of its autologous dendritic cell immunotherapy for Stage IV breast cancer patients, is pleased to announce the appointment of Dr. George E. Peoples, M.D., of Brooke Army Medical Center, San Antonio, TX to QI’s Scientific Advisory Board. [Quantum Immunologics, Inc. Press Release]

Roche’s Avastin Faces FDA Withdrawal in Breast Cancer
Roche Holding AG’s top-selling drug Avastin should no longer be used to treat breast cancer after recent studies failed to show a benefit, U.S. regulators said. [Bloomberg]


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


Visit our events page  to stay up to date with the latest events in the mammary cell community.


Lab Technologist – Cell Separation (STEMCELL Technologies)

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us